Pharmacy adherence pilot boosted refills 36%

Share this article:
Pharmacies that counseled patients for a chronic COPD/respiratory drug saw an average increase in refill rates of more than 36% through the fifth fill, said McKesson.

Counseling for a 90-day smoking cessation drug prompted a 30% increase in refill rates.

The company is piloting an adherence counseling program by which pharmacies are reimbursed by manufacturers for conducting five-minute intervention sessions with patients to improve adherence to prescribed drug regimens.

Participating pharmacists receive training in motivational interviewing and other behavioral techniques. In lieu of a script, they are given branded and unbranded “intervention tools” such as sample questions and responses to guide conversations with patients. Pharmacists, said McKesson, “were compensated in line with fair market value principles established  by the industry,” and the firm monitors transactional and performance data to safeguard against misreporting.

McKesson declined to name the two manufacturers that participated in the pilot but said tey'll be expanding the program to other chronic brands and that the company expects to add a number of brands with new clients to the program in 2010.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.